| 3VZV | date | ![]() |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| authors | |||||||||||||||
| compound | source | ||||||||||||||
| symmetry |
| ||||||||||||||
| crystal cell |
| ||||||||||||||
| method | X-Ray Diffraction | resolution | |||||||||||||
| ligand | VZV | enzyme |
| ||||||||||||
| Gene Ontology |
| ||||||||||||||
| Primary reference | Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold., Miyazaki M, Naito H, Sugimoto Y, Kawato H, Okayama T, Shimizu H, Miyazaki M, Kitagawa M, Seki T, Fukutake S, Aonuma M, Soga T, Bioorg Med Chem Lett. 2013 Feb 1;23(3):728-32. doi: 10.1016/j.bmcl.2012.11.091., Epub 2012 Dec 1. PMID:23266121 | ||||||||||||||
| Data retrieval |
![]() |
| View 3VZV in 3D |
Proteopedia, because life has more than 2D. |
| Structure-derived information |
| Sequence-derived information |
|
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |